Barclays analyst Alex Scott lowered the firm’s price target on Corebridge (CRBG) to $39 from $46 and keeps an Overweight rating on the shares as part of a Q3 preview for the life insurance group. The firm remains optimistic around fee-based earnings and group benefits. It does not see Q3 actuarial review “causing much noise this year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBG:
- Corebridge price target lowered to $39 from $40 at Morgan Stanley
- Corebridge price target lowered to $40 from $42 at Piper Sandler
- Corebridge Financial Reclassifies Variable Annuity Business
- Corebridge announces availability of life insurance products through Allstate
- Corebridge Financial Approves Retention Awards for Executives